Agile Therapeutics, Inc. provided revenue guidance for the First quarter 2023. For the period, the Company expects net revenue is expected to be in the range of $3.8 to $4.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3755 USD | +0.13% | -2.21% | -80.74% |
Mar. 28 | Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024 | |
Mar. 28 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M | MT |
1st Jan change | Capi. | |
---|---|---|
-80.74% | 2.57M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- AGRX Stock
- News Agile Therapeutics, Inc.
- Agile Therapeutics, Inc. Provides Revenue Guidance for the First Quarter 2023